Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD

• IGHV unmutated and ZAP-70-positive CLL patients have higher blood and tissue CLL death rates on ibrutinib therapy

• This result in lower residual disease levels with long-term ibrutinib in IGHV unmutated and ZAP-70-positive patients with CLL

Deuterated ("heavy") water labeling in CLL patients demonstrates that IGHV unmutated and ZAP-70-positive patients have higher blood and tissue CLL death rates on ibrutinib therapy, resulting in lower measurable residual disease (MRD) levels with long-term ibrutinib treatment. #NCT01752426.